LMR Partners’s Compass Therapeutics CMPX Stock Holding History

LMR Partners’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$159K	Buy	+30,000	New	+$173K	﹤0.01%	1219
2025 Q2	–	Sell	-60,000	Closed	-$114K	–	1421
2025 Q1	$114K	Buy	+60,000	New	+$160K	﹤0.01%	1131

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LMR Partners's CMPX Position: Q3 2023 in Review

LMR Partners sold out of Compass Therapeutics (CMPX) in Q3 2023, closing a stake of 80,692 shares — an estimated $257K sold.

LMR Partners first reported a position in CMPX in Q4 2021 and held it in 7 quarters. The position peaked at $628K in Q4 2022. 76 funds tracked by Wall St. Rank hold CMPX as of Q3 2023.

LMR Partners reported no remaining Compass Therapeutics position as of Q3 2023 after selling out during the quarter.
LMR Partners sold 80,692 Compass Therapeutics shares in Q3 2023, an estimated $257K.
LMR Partners first reported a position in Compass Therapeutics in Q4 2021 and held it in 7 quarters.
LMR Partners's Compass Therapeutics position peaked at $628K in Q4 2022.
76 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2023.

Based on LMR Partners's 13F filing for Q3 2023, filed 14 Nov 2023.